Skip to main content

Beatriz Minguez Rosique

Institutions of which they are part

Main researcher
Liver Diseases
Vall Hebron Institut de Recerca

Beatriz Minguez Rosique

Institutions of which they are part

Main researcher
Liver Diseases
Vall Hebron Institut de Recerca

Projects

Malalties Hepatobiliars (GRC)

IP: Rafael Esteban Mur
Collaborators: Beatriz Minguez Rosique, Immaculada Raurell Saborit, Lluís Viladomiu Catà, Antonio González Fernández, Lluis Castells Fusté, Maria del Mar Riveiro Barciela, Francisco Rodríguez Frias, Silvia Sauleda Oliveras, Victor Manuel Vargas Blasco, Maria Buti Ferret, Torrens Buscató, Maria Margarita, Josep Quer Sivila, Josep Gregori Font, Maria Nieves Martell Pérez-Alcalde, Damir Garcia Cehic, Juan Ignacio Esteban Mur, Meritxell Ventura Cots, Macarena Simon-Talero Horga, Joan Genescà Ferrer, David Tabernero Caellas
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 65000
Reference: 2014 SGR 421
Duration: 01/01/2014 - 31/12/2016

Lipotoxicity, Hepatic Steatosis and Hepatocarcinoma: role of the Armc10/Armcx family of mitochondrial proteins

IP: Beatriz Minguez Rosique
Collaborators: Monica Higuera Urbano
Funding agency: Fundació La Marató de TV3
Funding: 98437.5
Reference: 20133732
Duration: 14/03/2014 - 13/03/2017

Terapia molecular del carcinoma hepatocelular mediante inhibición de las vías de señalización PI3K/AKT y EFGR

IP: -
Collaborators: Beatriz Minguez Rosique
Funding agency: Ministerio de Educación, Cultura y Deporte
Funding:
Reference: FULBRIGHT_01_2008
Duration: 01/12/2008 - 30/11/2009

Efectos de la infusión de albúmina en el episodio de encefalopatía hepática. Estudio aleatorio y multicéntrico en pacientes con cirrosis hepática

IP: Victor Manuel Vargas Blasco
Collaborators: Beatriz Minguez Rosique, Juli Alonso Farre, Meritxell Ventura Cots
Funding agency: Instituto de Salud Carlos III
Funding: 71390
Reference: PI070641
Duration: 01/01/2008 - 30/12/2011

Related news

Preliminary study results confirm that the drug resmetirom reduces the presence of fat, inflammation, cell damage and fibrosis in the liver.

The European project, in which Vall d'Hebron participates, will favor personalized diagnosis and innovative therapeutic strategies in patients with the disease.

The research team used nanotechnology to deliver the drug directly to liver cells, which eliminated side effects without reducing effectiveness.

Related professionals

Cristina Vetoret Vázquez

Cristina Vetoret Vázquez

Research assistant
Clinical Neuroimmunology
Read more
Melissa Bradbury Lobato

Melissa Bradbury Lobato

Biomedical Research in Gynaecology
Read more
Norberto Núñez Seral

Norberto Núñez Seral

Tècnic/a Superior Recerca
High Technology Unit (UAT)
Preclinical Core Facilities
Core Facilities Area
Read more
María  Puigcerver  Mas

María Puigcerver Mas

Physiology and Pathophysiology of the Digestive Tract
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.